Ссылки
1. Danish National Board of Health. [List of permissions for physicians and dentists]. Available online at: http://ext.laegemiddelstyrelsen.dk/tilladelselaegertandlaeger/tilladelse_laeger – tandlaeger_full_soeg.asp?vis=hele (accessed November 2010).
2. Gagnon M.-A. Corporate influence over clinical research: considering the alternatives. Rev Prescrire. 2012; 32: 311–14.
3. Light D. W., Lexchin J. R. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.
4. Derry C. J., Derry S., Moore R. A. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012; 2: CD008615.
5. Tfelt-Hansen P. C. Unpublished clinical trials with sumatriptan. Lancet. 2009: 374: 1501–2.
6. Tfelt-Hansen P., Hauchildt Juhl H. [Treatment of migraine with triptans – a commented foreign health technology assessment]. Copenhagen: Sundhedsstyrelsen; 2008.
7. Spielmans G. I., Parry P. I. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethical Inquiry. 2010. DOI 10.1007/s11673-010-9208-8.
8. Grill M. Kranke Gesch?fte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
9. Sox H. C., Rennie D. Seeding trials: just say ‘no’. Ann Intern Med. 2008; 149: 279–80.
10. Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.
11. Andersen M., Kragstrup J., S?ndergaard J. How conducting a clinical trial affects physicians’ guideline adherence and drug preferences. JAMA. 2006; 295: 2759–64.
12. Psaty B. M., Rennie D. Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry. JAMA. 2006; 295: 2787–90.
13. Nielsen H. L. Linking Healthcare: an inquiry into the changing performances of web-based technology for asthma monitoring [PhD dissertation]. Copenhagen Business School, Department of Organization and Industrial Sociology; 2005.
14. Jackson T. Are you being duped? BMJ. 2001; 322: 1312.
15. Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
16. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
17. Henry D., Doran E., Kerridge I., et al. Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry. Arch Intern Med. 2005; 165: 2493–6.
18. Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian. 2004 Oct 5.
19. Abelson R. Whistle-blower suit says device maker generously rewards doctors. New York Times. 2006 Jan 24.
20. Thompson M., Heneghan C. BMJ open data campaign: time to move the debate forward. BMJ 2012; 345: 25.
21. Godlee F. Open letter to Roche about oseltamivir trial data. BMJ. 2012; 345: e7305.
22. Moore J. Medical device payments to doctors draw scrutiny. Star Tribune. 2008 Sept 8.
23. Lenzer J. Doctor’s group files legal charges against nine French doctors over competing interests.BMJ. 2009; 338: 1408.
24. Moynihan R. Key opinion leaders, independent experts of drug representatives in disguise? BMJ. 2008; 336: 1402–3.
25. Steinman M. A., Bero L. A., Chren M. M., et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006; 145: 284–93.
26. [Guidelines for the requirement of physicians and dentists to get permission to be connected to a drug company]. Copenhagen: Sundhedsstyrelsen; 2011 June 28.
27. Boseley S. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian. 2002 Feb 7.
28. Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004; 34: 18–23.
29. Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.
30. Bowman M. A., Pearle D. L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13–20.
31. Bowman M. A. The impact of drug company funding on the content of continuing medical education. Mubius. 1986; 6: 66–9.
32. Moynihan R. Doctors’ education: the invisible influence of drug company sponsorship. BMJ. 2008; 336: 416–17.
33. Burton B., Rowell A. Disease Mongering. SpinWatch. 2003. Available online at: www.spin
34. watch.org/component/content/article/47-pharma-industry/29-disease-mongering (accessed 11 November 2012). Key Opinion Leaders Europe. Conference announcement. SMI. 2009 June 15–16.
35. Can I buy you a dinner? Pharmaceutical companies increasingly use doctors’ talks as sales pitches. 2005 Aug. Available online at: www.worstpills.org (accessed August 2005).
36. Wilmshurst P. Academia and industry. Lancet. 2000; 356: 338–44.
37. Carlat D. Dr drug rep. New York Times. 2007 Nov 25.
38. Fugh-Berman A., Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med. 2007; 4: e150.
39. Blum A., Solberg E., Wolinsky H. The Surgeon General’s report on smoking and health 40 years later: still wandering in the desert. Lancet. 2004; 363: 97–8.
40. Rossouw J. E., Anderson G. L., Prentice R. L., et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288: 321–33.
41. Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
42. Clark J. A hot flush for big pharma. BMJ. 2003; 327: 400.
43. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefield; 2008.
44. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
45. Wise J. European drug agency criticises Roche for failing to report adverse reactions and patient deaths. BMJ. 2012; 344: e4344.
